HeXun Biosciences（6986）株式概要HeXun Biosciences Co, Ltd.は台湾で幹細胞および治療法の研究開発を行っている。 詳細6986 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績2/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より51.8%で取引されている リスク分析意味のある時価総額がありません ( NT$3B )すべてのリスクチェックを見る6986 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueNT$Current PriceNT$54.5034.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-43m293m2016201920222025202620282031Revenue NT$293.2mEarnings NT$111.9mAdvancedSet Fair ValueView all narrativesHeXun Biosciences Co., Ltd. 競合他社BioLASCO TaiwanSymbol: TPEX:6662Market cap: NT$753.0mRBC BioscienceSymbol: TPEX:6848Market cap: NT$294.7mPet Pharm BiotechSymbol: TPEX:7762Market cap: NT$2.9bBonraybioSymbol: TWSE:6955Market cap: NT$3.1b価格と性能株価の高値、安値、推移の概要HeXun Biosciences過去の株価現在の株価NT$54.5052週高値NT$75.3052週安値NT$50.00ベータ-0.0441ヶ月の変化-9.47%3ヶ月変化-9.32%1年変化-27.33%3年間の変化n/a5年間の変化n/aIPOからの変化-39.71%最新ニュースReported Earnings • Apr 06Full year 2025 earnings released: EPS: NT$2.43 (vs NT$3.20 in FY 2024)Full year 2025 results: EPS: NT$2.43 (down from NT$3.20 in FY 2024). Revenue: NT$293.2m (up 2.4% from FY 2024). Net income: NT$111.9m (down 24% from FY 2024). Profit margin: 38% (down from 51% in FY 2024). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Mar 18Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$58.90, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 34x in the Life Sciences industry in Asia. Total loss to shareholders of 29% over the past year.お知らせ • Mar 13HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 16, 2026HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 16, 2026. Location: 7 floor no,1490, ch`un jih rd., taoyuan district, taoyuan city TaiwanReported Earnings • Dec 30Third quarter 2025 earnings released: EPS: NT$0.29 (vs NT$0.76 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.29 (down from NT$0.76 in 3Q 2024). Revenue: NT$56.6m (down 26% from 3Q 2024). Net income: NT$13.6m (down 61% from 3Q 2024). Profit margin: 24% (down from 46% in 3Q 2024). The decrease in margin was primarily driven by lower revenue.Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$66.00, the stock trades at a trailing P/E ratio of 23.1x. Average trailing P/E is 21x in the Life Sciences industry in Taiwan. Total loss to shareholders of 13% over the past year.New Risk • Aug 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$2.98b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risk Market cap is less than US$100m (NT$2.98b market cap, or US$99.2m).最新情報をもっと見るRecent updatesReported Earnings • Apr 06Full year 2025 earnings released: EPS: NT$2.43 (vs NT$3.20 in FY 2024)Full year 2025 results: EPS: NT$2.43 (down from NT$3.20 in FY 2024). Revenue: NT$293.2m (up 2.4% from FY 2024). Net income: NT$111.9m (down 24% from FY 2024). Profit margin: 38% (down from 51% in FY 2024). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Mar 18Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$58.90, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 34x in the Life Sciences industry in Asia. Total loss to shareholders of 29% over the past year.お知らせ • Mar 13HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 16, 2026HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 16, 2026. Location: 7 floor no,1490, ch`un jih rd., taoyuan district, taoyuan city TaiwanReported Earnings • Dec 30Third quarter 2025 earnings released: EPS: NT$0.29 (vs NT$0.76 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.29 (down from NT$0.76 in 3Q 2024). Revenue: NT$56.6m (down 26% from 3Q 2024). Net income: NT$13.6m (down 61% from 3Q 2024). Profit margin: 24% (down from 46% in 3Q 2024). The decrease in margin was primarily driven by lower revenue.Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$66.00, the stock trades at a trailing P/E ratio of 23.1x. Average trailing P/E is 21x in the Life Sciences industry in Taiwan. Total loss to shareholders of 13% over the past year.New Risk • Aug 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$2.98b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risk Market cap is less than US$100m (NT$2.98b market cap, or US$99.2m).New Risk • Apr 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.28b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (NT$3.28b market cap, or US$99.1m).Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$70.00, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 26x in the Life Sciences industry in Taiwan. Total returns to shareholders of 19% over the past year.Reported Earnings • Apr 02Full year 2024 earnings released: EPS: NT$3.20 (vs NT$0.74 in FY 2023)Full year 2024 results: EPS: NT$3.20 (up from NT$0.74 in FY 2023). Revenue: NT$286.4m (up 119% from FY 2023). Net income: NT$147.2m (up 340% from FY 2023). Profit margin: 51% (up from 26% in FY 2023). The increase in margin was driven by higher revenue.お知らせ • Mar 19HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 03, 2025HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 03, 2025, at 09:30 Taipei Standard Time. Location: 7 floor no,1490, ch`un jih rd., taoyuan district, taoyuan city TaiwanNew Risk • Mar 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.2% average weekly change).Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$89.50, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 29x in the Life Sciences industry in Taiwan. Total returns to shareholders of 60% over the past year.New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).Valuation Update With 7 Day Price Move • Dec 30Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$65.20, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 36x in the Life Sciences industry in Asia. Negligible returns to shareholders over past year.New Risk • Nov 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.23b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risk Market cap is less than US$100m (NT$3.23b market cap, or US$99.8m).お知らせ • Mar 29HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 12, 2024HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 12, 2024.New Risk • Nov 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.14b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risk Market cap is less than US$100m (NT$3.14b market cap, or US$98.7m).株主還元6986TW Life SciencesTW 市場7D-4.4%6.8%0.5%1Y-27.3%-2.0%103.9%株主還元を見る業界別リターン: 6986過去 1 年間で-2 % の収益を上げたTW Life Sciences業界を下回りました。リターン対市場: 6986は、過去 1 年間で103.9 % のリターンを上げたTW市場を下回りました。価格変動Is 6986's price volatile compared to industry and market?6986 volatility6986 Average Weekly Movement4.9%Life Sciences Industry Average Movement5.5%Market Average Movement6.4%10% most volatile stocks in TW Market12.0%10% least volatile stocks in TW Market2.6%安定した株価: 6986 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 6986の 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201953Simon Huangwww.hexunbio.com台湾で幹細胞や治療法の研究開発を行う和順生物科技股份有限公司。受託製造サービス、各種細胞および細胞誘導体の受託開発・製造サービス、受託検査、アドバイザリー、実験室情報管理システム、無菌充填サービスを提供している。同社は2019年に設立され、台湾の桃園市に拠点を置く。もっと見るHeXun Biosciences Co., Ltd. 基礎のまとめHeXun Biosciences の収益と売上を時価総額と比較するとどうか。6986 基礎統計学時価総額NT$2.51b収益（TTM）NT$111.91m売上高(TTM)NT$293.23m22.4xPER（株価収益率8.5xP/Sレシオ6986 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計6986 損益計算書（TTM）収益NT$293.23m売上原価NT$26.95m売上総利益NT$266.28mその他の費用NT$154.37m収益NT$111.91m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）2.43グロス・マージン90.81%純利益率38.16%有利子負債／自己資本比率0%6986 の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.4%現在の配当利回り9%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/25 01:38終値2026/06/25 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋HeXun Biosciences Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Apr 06Full year 2025 earnings released: EPS: NT$2.43 (vs NT$3.20 in FY 2024)Full year 2025 results: EPS: NT$2.43 (down from NT$3.20 in FY 2024). Revenue: NT$293.2m (up 2.4% from FY 2024). Net income: NT$111.9m (down 24% from FY 2024). Profit margin: 38% (down from 51% in FY 2024). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Mar 18Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$58.90, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 34x in the Life Sciences industry in Asia. Total loss to shareholders of 29% over the past year.
お知らせ • Mar 13HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 16, 2026HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 16, 2026. Location: 7 floor no,1490, ch`un jih rd., taoyuan district, taoyuan city Taiwan
Reported Earnings • Dec 30Third quarter 2025 earnings released: EPS: NT$0.29 (vs NT$0.76 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.29 (down from NT$0.76 in 3Q 2024). Revenue: NT$56.6m (down 26% from 3Q 2024). Net income: NT$13.6m (down 61% from 3Q 2024). Profit margin: 24% (down from 46% in 3Q 2024). The decrease in margin was primarily driven by lower revenue.
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$66.00, the stock trades at a trailing P/E ratio of 23.1x. Average trailing P/E is 21x in the Life Sciences industry in Taiwan. Total loss to shareholders of 13% over the past year.
New Risk • Aug 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$2.98b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risk Market cap is less than US$100m (NT$2.98b market cap, or US$99.2m).
Reported Earnings • Apr 06Full year 2025 earnings released: EPS: NT$2.43 (vs NT$3.20 in FY 2024)Full year 2025 results: EPS: NT$2.43 (down from NT$3.20 in FY 2024). Revenue: NT$293.2m (up 2.4% from FY 2024). Net income: NT$111.9m (down 24% from FY 2024). Profit margin: 38% (down from 51% in FY 2024). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Mar 18Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$58.90, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 34x in the Life Sciences industry in Asia. Total loss to shareholders of 29% over the past year.
お知らせ • Mar 13HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 16, 2026HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 16, 2026. Location: 7 floor no,1490, ch`un jih rd., taoyuan district, taoyuan city Taiwan
Reported Earnings • Dec 30Third quarter 2025 earnings released: EPS: NT$0.29 (vs NT$0.76 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.29 (down from NT$0.76 in 3Q 2024). Revenue: NT$56.6m (down 26% from 3Q 2024). Net income: NT$13.6m (down 61% from 3Q 2024). Profit margin: 24% (down from 46% in 3Q 2024). The decrease in margin was primarily driven by lower revenue.
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$66.00, the stock trades at a trailing P/E ratio of 23.1x. Average trailing P/E is 21x in the Life Sciences industry in Taiwan. Total loss to shareholders of 13% over the past year.
New Risk • Aug 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$2.98b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risk Market cap is less than US$100m (NT$2.98b market cap, or US$99.2m).
New Risk • Apr 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.28b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (NT$3.28b market cap, or US$99.1m).
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$70.00, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 26x in the Life Sciences industry in Taiwan. Total returns to shareholders of 19% over the past year.
Reported Earnings • Apr 02Full year 2024 earnings released: EPS: NT$3.20 (vs NT$0.74 in FY 2023)Full year 2024 results: EPS: NT$3.20 (up from NT$0.74 in FY 2023). Revenue: NT$286.4m (up 119% from FY 2023). Net income: NT$147.2m (up 340% from FY 2023). Profit margin: 51% (up from 26% in FY 2023). The increase in margin was driven by higher revenue.
お知らせ • Mar 19HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 03, 2025HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 03, 2025, at 09:30 Taipei Standard Time. Location: 7 floor no,1490, ch`un jih rd., taoyuan district, taoyuan city Taiwan
New Risk • Mar 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.2% average weekly change).
Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$89.50, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 29x in the Life Sciences industry in Taiwan. Total returns to shareholders of 60% over the past year.
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
Valuation Update With 7 Day Price Move • Dec 30Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$65.20, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 36x in the Life Sciences industry in Asia. Negligible returns to shareholders over past year.
New Risk • Nov 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.23b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risk Market cap is less than US$100m (NT$3.23b market cap, or US$99.8m).
お知らせ • Mar 29HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 12, 2024HeXun Biosciences Co., Ltd., Annual General Meeting, Jun 12, 2024.
New Risk • Nov 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.14b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risk Market cap is less than US$100m (NT$3.14b market cap, or US$98.7m).
